NABL stock news
This page provides real-time market news, earnings updates, and company announcements related to N-able, Inc. (NABL).
All content is aggregated from trusted financial media and market data sources to help investors stay informed about key market movements and corporate developments.
Last updated as of 2026-04-15 12:42 EST
Cytokinetics Announces European Commission Approval of MYQORZO (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
Finviz2026-02-17 12:33:42
NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update
Finviz2026-02-18 12:03:22
Omada Adds Cholesterol Care to Its Integrated Platform, Addressing the Silent Driver of Cardiovascular Risk
Finviz2026-02-19 14:03:34
Omada Adds Cholesterol Care to Its Integrated Platform, Addressing the Silent Driver of Cardiovascular Risk
Finviz2026-02-19 14:03:34
BMO and Needham Lower N-able (NABL) Price Targets
Finviz2026-02-23 15:00:11
PennantPark Floating Rate Capital Ltd. Completes the Reset of a $356.5 Million Securitization, Substantially Reducing Borrowing Costs
Finviz2026-02-25 00:06:37
N-able (NABL) Reports $130M Q4 Revenue and Strong 30% Adjusted EBITDA Margins
Finviz2026-02-26 19:33:11
Farmer Brothers to Be Acquired by Royal Cup, Creating a Scaled, Integrated Beverage Solutions Platform
Finviz2026-03-04 14:09:45
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
Finviz2026-03-10 11:36:05
Monroe Capital Corporation Announces $13.0 Million Increase in Special Pre-Merger Closing Distribution for Monroe Capital Corporation Stockholders Resulting in a $15.9 Million ($0.75 per share) Total Pre-Merger Closing Distribution
Finviz2026-03-10 13:18:53
FiEE, Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results
Finviz2026-03-20 20:06:48
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
Finviz2026-03-23 11:36:10
Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Finviz2026-03-23 12:33:50
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy
Finviz2026-03-31 12:06:47
AirSculpt Technologies Reports Fourth Quarter and Full Year Fiscal 2025 Results
Finviz2026-04-02 10:33:56
CORRECTION -- AirSculpt Technologies Reports Fourth Quarter and Full Year Fiscal 2025 Results
Finviz2026-04-06 10:33:42
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE
Finviz2026-04-06 13:03:55
Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL
Finviz2026-04-13 11:33:06
BMO and Needham Lower N-able (NABL) Price Targets
Finviz2026-02-23 15:00:11
PennantPark Floating Rate Capital Ltd. Completes the Reset of a $356.5 Million Securitization, Substantially Reducing Borrowing Costs
Finviz2026-02-25 00:06:37
N-able (NABL) Reports $130M Q4 Revenue and Strong 30% Adjusted EBITDA Margins
Finviz2026-02-26 19:33:11
Farmer Brothers to Be Acquired by Royal Cup, Creating a Scaled, Integrated Beverage Solutions Platform
Finviz2026-03-04 14:09:45
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
Finviz2026-03-10 11:36:05
Monroe Capital Corporation Announces $13.0 Million Increase in Special Pre-Merger Closing Distribution for Monroe Capital Corporation Stockholders Resulting in a $15.9 Million ($0.75 per share) Total Pre-Merger Closing Distribution
Finviz2026-03-10 13:18:53
FiEE, Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results
Finviz2026-03-20 20:06:48
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
Finviz2026-03-23 11:36:10
Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Finviz2026-03-23 12:33:50
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy
Finviz2026-03-31 12:06:47
AirSculpt Technologies Reports Fourth Quarter and Full Year Fiscal 2025 Results
Finviz2026-04-02 10:33:56
CORRECTION -- AirSculpt Technologies Reports Fourth Quarter and Full Year Fiscal 2025 Results
Finviz2026-04-06 10:33:42
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE
Finviz2026-04-06 13:03:55
Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL
Finviz2026-04-13 11:33:06
NABL stock chart
NABL stock detailsNABL stock price change
On the last trading day, NABL stock closed at 4.60 USD, with a price change of 9.26% for the day.
Trade stock perpsAbout Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn more